Aortic valve stenosis
Drug research and approvals for aortic valve stenosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 262 studies of aortic valve stenosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 4 drug trials for it since 2013.
- Recruiting worldwide: 262
- Trials authorized in Canada: 4
- FDA orphan approvals: 0
- EU medicines: 0
- A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol…NCT07950358 · Not applicable · Ligang Ding · starts Nov 16, 2026
- SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic StenosisNCT07944066 · Phase 4 · Samsung Medical Center · starts Jun 10, 2026
- TAVI and PCI in Comparison to SAVR and CABG in Low and Intermediate Risk Patients With Severe Aortic StenosisNCT07926022 · Not reported · Alexandria University · starts Feb 1, 2026
- Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT…NCT07908355 · Not reported · American College of Cardiology · starts Sep 1, 2026
- Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI TrialNCT07895719 · Not applicable · University Hospital of Ferrara · starts Nov 4, 2026
- SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY…NCT07872020 · Not applicable · Erasmus Medical Center · starts Oct 26, 2026
- Association Between Changes in Aortic Valve Area and Pulmonary Congestion After Transcatheter Aortic Valve ImplantationNCT07794436 · Not reported · Istanbul University - Cerrahpasa · starts Mar 31, 2026
- BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07755904 · Phase 3 · Braveheart Bio, Inc. · starts Sep 2, 2026
- Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis -…NCT07752732 · Not reported · University Hospital Tuebingen · starts Jan 14, 2020
Phase 3 12 of 15
- ApixabanCoagulation factor X inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- ClopidogrelPurinergic receptor P2Y12 antagonist
- EdoxabanCoagulation factor X inhibitor
- AspirinCyclooxygenase inhibitor
- EzetimibeNiemann-Pick C1-like protein 1 inhibitor
- CandesartanType-1 angiotensin II receptor antagonist
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- RivaroxabanCoagulation factor X inhibitor
- SpironolactoneMineralocorticoid receptor antagonist
- BivalirudinThrombin inhibitor
- HeparinAntithrombin-III activator
Phase 2 6
- AtaciguatSoluble guanylate cyclase activator
- MetoprololBeta-1 adrenergic receptor antagonist
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- Alendronic acidFarnesyl diphosphate synthase inhibitor
- FluvastatinHMG-CoA reductase inhibitor
- Sodium fluoride
Phase 1 or earlier 1
How its trials ended
889 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 159 whose ending is known, 43% met their primary endpoint, 7% missed it and 50% stopped early.
- Ongoing30034%
- Completed, result not reported27831%
- Status unknown15217%
- Met its primary endpoint698%
- Stopped: other or unclear445%
- Stopped: sponsor or business decision142%
- Stopped: enrollment or feasibility121%
- Missed its primary endpoint111%
- Stopped: funding4<1%
- Stopped: lack of efficacy3<1%
- Stopped: safety2<1%
| Jul 30, 2025 | A phase 2b, randomized, double-blinded, placebo controlled study checking the efficacy and safety of ataciguat to slow the progression of valvular dysfunction…Ataciguat (HMR1766) | Kardigan | Ongoing |
| Jun 26, 2024 | An adaptive phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2-arm study to evaluate the efficacy and safety of DA-1229…Evogliptin (DA-1229) | Rednvia Co., Ltd. | Ongoing |
| Feb 21, 2023 | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of…Pelacarsen (TQJ230) | Novartis Pharmaceuticals | Ongoing |
| Apr 22, 2022 | Effect of colchicine on the progression of aortic valve stenosis (COPAS) [placebo controlled]Colchicine / Sodium fluoride 18F | Ottawa Heart Institute Research Corporation | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA